Saturday, 31 October 2026European Markets

AIRTHINGS Stock Jump Before The Weekend, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with AIRTHINGS (AIRX.OL) rising 9.8% to kr2.80 on Friday while Oslo Børs Benchmark Index_GI dropped 1.03% to kr1,201.04.

AIRTHINGS's last close was kr2.55, 55.57% below its 52-week high of kr5.74.

About AIRTHINGS

Airthings ASA, a hardware-enabled software company, develop products and systems for monitoring indoor air quality, radon, and energy efficiency worldwide. It operates through Consumer, Business, and Professional segments. The Consumer segments sells air quality sensors to private customers through retail and e-commerce. Its Business segment provides air quality solutions to schools, office building, and other commercial buildings. The Professional segment sells measurement solutions, which enables inspectors and certified radon professionals to measure, analyze, and report on buildings; and offers rental of products and calibration services. In addition, it offers digital radon detectors as well as smart indoor air quality monitors and solutions. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. Airthings ASA was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, AIRTHINGS has a trailing twelve months EPS of kr-0.54.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -16.08%.

Moving Average

AIRTHINGS's value is higher than its 50-day moving average of kr2.68 and way under its 200-day moving average of kr3.69.

More news about AIRTHINGS (AIRX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com